Silencing ZEB2 decreases cancer stem properties in high-grade ovarian cancer, reduces tumoral clonogenicity, and downregulates cancer stem cell-related factors, like NANOG and Oct4 (Li et al., 2021[65]). Here, ZEB2 is linked to ovarian carcinoma.